AMALRIC Marianne
Onglets principaux
marianne.amalric@univ-amu.fr
Equipe(s) de recherche
Cognition et pathophysiologie des ganglions de la base
Publications in HAL
http://api.archives-ouvertes.fr/search/?&fq=authLastNameFirstName_s:%28%22Amalric+Marianne%22%29&fl=title_s,en_title_s,docid,label_s,en_label_s,docType_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s&sort=producedDate_tdate+desc
- A. M. Ouagazzal, A. Ces, S. Di Bisceglie Caballero, Frédéric Ambroggi, Marianne Amalric. Effects of external globus pallidus photostimulation on motor behavior in normal and hemi-parkinsonian mice. XIIIth International Basal Ganglia Society (IBAGS) meeting, Apr 2019, Biarritz, France. ⟨hal-02556654⟩
- Samira Ztaou, Marianne Amalric. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s disease. Neurochemistry International, Elsevier, 2019. ⟨hal-02385017⟩
- Samira Ztaou, Juliette Lhost, Isabelle Watabe, Giulia Torromino, Marianne Amalric. Striatal cholinergic interneurons regulate cognitive and affective dysfunction in partially dopamine-depleted mice. European Journal of Neuroscience, Wiley, 2018, 48 (9), pp.2988-3004. ⟨10.1111/ejn.14153⟩. ⟨hal-01974268⟩
- Christiane Mourre, Christine Manrique, Jeremy Camon, Sabrine Aidi-Knani, Thierry Deltheil, et al.. Changes in SK channel expression in the basal ganglia after partial nigrostriatal dopamine lesions in rats: Functional consequences. Neuropharmacology, Elsevier, 2017, 113, Part A, pp.519-532. ⟨10.1016/j.neuropharm.2016.11.003⟩. ⟨hal-01470385⟩
- Samira Ztaou, Nicolas Maurice, Jeremy Camon, Gaëlle Guiraudie-Capraz, Lydia Kerkerian-Le Goff, et al.. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease. Journal of Neuroscience, Society for Neuroscience, 2016, 36 (35), pp.9161-9172. ⟨10.1523/JNEUROSCI.0873-16.2016⟩. ⟨hal-01478864⟩
- S. Ztaou, N. Maurice, J. Camon, G. Guiraudie-Capraz, L. Kerkerian-Legoff, et al.. Involvement of striatal cholinergic interneurons, M1 and M4 muscarinic receptors in motor symptoms of Parkinson's disease. Journal of Neuroscience, Society for Neuroscience, 2016, 36 (35), pp.9161-72. ⟨10.1523/JNEUROSCI.0873-16.2016.⟩. ⟨hal-01444590⟩
- Samira Ztaou, Nicolas Maurice, Jeremy Camon, Gaëlle Guiraudie-Capraz, Lydia Kerkerian-Le Goff, et al.. Neurobiology of Disease Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease. Journal of Neuroscience, Society for Neuroscience, 2016, 36 (35), pp.9161-9172. ⟨10.1523/JNEUROSCI.0873-16.2016⟩. ⟨hal-01470425⟩
- Nicolas Maurice, Martine Liberge, Florence Jaouen, Samira Ztaou, Marwa Hanini, et al.. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Reports, Elsevier Inc, 2015, 13 (4), pp.657-666. ⟨10.1016/j.celrep.2015.09.034⟩. ⟨hal-02332256⟩
- Nicolas Maurice, Martine Liberge, Florence Jaouen, Samira Ztaou, Marwa Hanini, et al.. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Reports, Elsevier Inc, 2015, 13 (4), pp.657-666. ⟨10.1016/j.celrep.2015.09.034⟩. ⟨hal-02332092⟩
- Sabrine Aidi-Knani, Imed Regaya, Marianne Amalric, Christiane Mourre. Kv4 channel blockade reduces motor and neuropsychiatric symptoms in rodent models of Parkinson's disease. Behavioural Pharmacology, Lippincott, Williams & Wilkins, 2015, 26 (1-2, SI), pp.91-100. ⟨10.1097/FBP.0000000000000107⟩. ⟨hal-01384019⟩
- Marianne Amalric. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease. Current Opinion in Pharmacology, Elsevier, 2015, 20, pp.29-34. ⟨10.1016/j.coph.2014.11.001⟩. ⟨hal-01384021⟩
- Nicolas Maurice, Thierry Deltheil, Christophe Melon, Bertrand Degos, Christiane Mourre, et al.. Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease. PLoS ONE, Public Library of Science, 2015, 10 (11), pp.e0142838. ⟨10.1371/journal.pone.0142838⟩. ⟨hal-01384032⟩
- D. Revy, F. Jaouen, Pascal Salin, C. Melon, D. Chabbert, et al.. Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions. Neuropsychopharmacology, Nature Publishing Group, 2014, 39 (11), pp.2662-72. ⟨10.1038/npp.2014.121⟩. ⟨hal-01112489⟩
- Thierry Deltheil, Nathalie Turle-Lorenzo, Marianne Amalric. Effects of Group III mGluR Modulation in the Globus Pallidus of Parkinsonian Rats. Current Neuropharmacology, Bentham Science Publishers, 2014, 12 (1), pp.13-14. ⟨hal-01384058⟩
- Lin Chen, Thierry Deltheil, Nathalie Turle-Lorenzo, Martine Liberge, Corinne Rosier, et al.. SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats. International Journal of Neuropsychopharmacology, Oxford University Press (OUP), 2014, 17 (8), pp.1295-1306. ⟨10.1017/S1461145714000236⟩. ⟨hal-01384068⟩
- Marianne Amalric, S. Lopez, C. Goudet, G. Fisone, G. Battaglia, et al.. Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology, Elsevier, 2013, 66 (SI), pp.53-64. ⟨10.1016/j.neuropharm.2012.05.026⟩. ⟨hal-01384098⟩
- Francesca Manago, Sébastien Lopez, Alberto Oliverio, Marianne Amalric, Andrea Mele, et al.. Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice. Psychopharmacology, Springer Verlag, 2013, 226 (3), pp.541-550. ⟨10.1007/s00213-012-2925-4⟩. ⟨hal-01384085⟩
- S. Lopez, L. Jouve, N. Turle-Lorenzo, L. Kerkerian-Legoff, P. Salin, et al.. Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.. Neurobiology of Disease, Elsevier, 2012, 46 (1), pp.69-77. ⟨10.1016/j.nbd.2011.12.045⟩. ⟨hal-00843334⟩
- Cyril Goudet, Bruno Vilar, Tiphanie Courtiol, Thierry Deltheil, Thomas Bessiron, et al.. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.. FASEB Journal, Federation of American Society of Experimental Biology, 2012, 26 (4), pp.1682-93. ⟨10.1096/fj.11-195941⟩. ⟨hal-01182946⟩
- Carrie K. Jones, Michael Bubser, Analisa D. Thompson, Jonathan W. Dickerson, Nathalie Turle-Lorenzo, et al.. The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2012, 340 (2), pp.404-421. ⟨10.1124/jpet.111.187443⟩. ⟨hal-01384126⟩
- A. Courtiere, J. Hardouin, Boris Burle, F. Vidal, N. Turle-Lorenzo, et al.. Dynamics of Executive Control and Motor Deficits in Parkinsonian Rats. Journal of Neuroscience, Society for Neuroscience, 2011, 31 (33), ⟨10.1523/JNEUROSCI.2550-11.2011⟩. ⟨hal-01308507⟩
- Cyril Goudet, Bruno Vilar, Tiphanie Courtiol, Thierry Deltheil, Thomas Bessiron, et al.. A new Selective Metabotropic Glutamate Receptor type 4 Agonist Reveals New ways to Develop Subtype Selective Orthosteric Ligands with Potential Therapeutic Effects. Current Neuropharmacology, Bentham Science Publishers, 2011, 9 (1), pp.26. ⟨hal-01384798⟩
- T. Deltheil, C. Rosier, N. Turle-Lorenzo, Lin Chen, C. Mourre, et al.. MODULATION OF POTASSIUM KCA2 CHANNELS AS AN ANTIPARKINSONIAN STRATEGY. Behavioural Pharmacology, Lippincott, Williams & Wilkins, 2011, 22 (S), pp.E45. ⟨hal-01384808⟩
- Roula Moussa, Bruno Poucet, Marianne Amalric, Francesca Sargolini. Contributions of dorsal striatal subregions to spatial alternation behavior. Learning and Memory, Cold Spring Harbor Laboratory Press, 2011, 18 (7), pp.444-451. ⟨10.1101/lm.2123811⟩. ⟨hal-01384807⟩
- Thierry Deltheil, Nathalie Turle-Lorenzo, Marianne Amalric. Orthosteric Group III mGlu Receptor Agonists for Parkinson's Disease Treatment: Symptomatic and Neurochemical Action on Pallidal Synaptic Transmission. Current Neuropharmacology, Bentham Science Publishers, 2011, 9 (1), pp.14-15. ⟨hal-01384803⟩
- B. Greco, S. Lopez, H. Putten, P. J. Flor, Marianne Amalric. Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2010, 332 (3), pp.1064-1071. ⟨10.1124/jpet.109.162115⟩. ⟨hal-01384809⟩
- Francine C. Acher, C. Selvam, N. Triballeau, N. Oueslati, I. Lemasson, et al.. A novel series of group III metabotropic glutamate receptor (mGluR) agonists. Abstracts of Papers of the American Chemical Society, American Chemical Society, 2009, 237. ⟨hal-01384834⟩
- Isabelle A. Lemasson, Chelliah Selvam, Nadia Oueslati, Isabelle Brabet, Tiphanie Courtiol, et al.. Is metabotropic glutamate receptor mGlu4R a good target to treat Parkinson's disease symptoms? Design and evaluation of potent and selective agonists. Abstracts of Papers of the American Chemical Society, American Chemical Society, 2009, 238. ⟨hal-01384832⟩
- C. Beurrier, S. Lopez, D. Revy, C. Selvam, C. Goudet, et al.. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB Journal, Federation of American Society of Experimental Biology, 2009, 23, pp.3619-3628. ⟨hal-00582954⟩
- Elvira de Leonibus, Francesca Manago, Francesco Giordani, Francesco Petrosino, Sébastien Lopez, et al.. Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease. Neuropsychopharmacology, Nature Publishing Group, 2009, 34 (3), pp.729-738. ⟨10.1038/npp.2008.129⟩. ⟨hal-01384831⟩
